Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

We report long-term clinical outcomes and immune responses observed from a phase 1 trial of agonist CD40 monoclonal antibody (mAb) and blocking CTLA-4 mAb in patients with metastatic melanoma. Twenty-four patients previously untreated with checkpoint blockade were enrolled. The agonistic CD40 mAb CP...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajor, David L., Mick, Rosemarie, Riese, Matthew J., Huang, Alex C., Sullivan, Brendan, Richman, Lee P., Torigian, Drew A., George, Sangeeth M., Stelekati, Erietta, Chen, Fang, Melenhorst, J. Joseph, Lacey, Simon F., Xu, Xiaowei, Wherry, E. John, Gangadhar, Tara C., Amaravadi, Ravi K., Schuchter, Lynn M., Vonderheide, Robert H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169575/
https://www.ncbi.nlm.nih.gov/pubmed/30288340
http://dx.doi.org/10.1080/2162402X.2018.1468956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169575/
https://www.ncbi.nlm.nih.gov/pubmed/30288340
http://dx.doi.org/10.1080/2162402X.2018.1468956

Ejemplares similares